Potential Drug Compound That Attacks Parkinson's Disease On Two Fronts Designed
In a new study published recently online ahead of print by the journal ACS Chemical Biology, the scientists describe a "dual inhibitor" - two compounds in a single molecule - that attacks a pair of proteins closely associated with development of Parkinson's disease.
"In general, these two enzymes amplify the effect of each other," said team leader Phil LoGrasso, a TSRI professor who has been a pioneer in the development of JNK inhibitors for the treatment of neurodegenerative diseases. "What we were looking for is a high-affinity, high-selectivity treatment that is additive or synergistic in its effect - a one-two punch."
That could be what they found.
This new dual inhibitor attacks two enzymes - the leucine-rich repeat kinase 2 (LRRK2) and the c-jun-N-terminal kinase (JNK) - pronounced "junk." Genetic testing of several thousand Parkinson's patients has shown that mutations in the LRRK2 gene increase the risk of Parkinson's disease, while JNK has been shown to play an important role in neuron (nerve cell) survival in a range of neurodegenerative diseases. As such, they have become highly viable targets for drugs to treat disorders such as Parkinson's disease.
A dual inhibitor ultimately would be preferred over separate individual JNK and LRRK2 inhibitors because a combination molecule would eliminate complications of drug-drug interactions and the need to optimize individual inhibitor doses for efficacy, the study noted.
Now the team's new dual inhibitor will need to be optimized for potency, high selectivity (which reduces off-target side effects) and bioavailability so it can be tested in animal models of Parkinson's disease.
The first author of the study, “A Small Molecule Bidentate-Binding Dual Inhibitor Probe of the LRRK2 and JNK Kinases,” is Yangbo Feng of TSRI. Other authors include Jeremy W. Chambers, Sarah Iqbal, Marcel Koenig, HaJeung Park, Lisa Cherry, Pamela Hernandez and Mariana Figuera-Losada.
The study was supported by the National Institutes of Health grant NS057153.
Scripps Research Institute
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Institute, Scripps Research. "Potential Drug Compound That Attacks Parkinson's Disease On Two Fronts Designed." Medical News Today. MediLexicon, Intl., 24 Jun. 2013. Web.
30 May. 2016. <http://www.medicalnewstoday.com/releases/262315.php>
Institute, S. (2013, June 24). "Potential Drug Compound That Attacks Parkinson's Disease On Two Fronts Designed." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.